Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd.

SHSE:603707 Stock Report

Market Cap: CN¥22.1b

Nanjing King-Friend Biochemical PharmaceuticalLtd Future Growth

Future criteria checks 5/6

Nanjing King-Friend Biochemical PharmaceuticalLtd is forecast to grow earnings and revenue by 71.2% and 23.9% per annum respectively. EPS is expected to grow by 71.4% per annum. Return on equity is forecast to be 16.6% in 3 years.

Key information

71.2%

Earnings growth rate

71.4%

EPS growth rate

Pharmaceuticals earnings growth19.2%
Revenue growth rate23.9%
Future return on equity16.6%
Analyst coverage

Low

Last updated29 Apr 2024

Recent future growth updates

Recent updates

Earnings and Revenue Growth Forecasts

SHSE:603707 - Analysts future estimates and past financials data (CNY Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20266,8191,652N/A7152
12/31/20256,0711,545N/A9684
12/31/20244,373923N/A9792
3/31/20243,628-3451,2691,698N/A
12/31/20233,931-1891,2001,619N/A
9/30/20234,0041,0238291,135N/A
6/30/20234,0411,101437727N/A
3/31/20233,8441,093142466N/A
12/31/20223,7131,091125595N/A
9/30/20223,7581,1224941,069N/A
6/30/20223,9111,1184621,035N/A
3/31/20223,9801,116376929N/A
12/31/20213,6871,059243684N/A
9/30/20213,5371,038-163242N/A
6/30/20213,270953-478-99N/A
3/31/20213,064875-820-469N/A
12/31/20202,915806-860-566N/A
9/30/20202,800770-869-761N/A
6/30/20202,689724-916-816N/A
3/31/20202,594660-850-744N/A
12/31/20192,470605-957-841N/A
9/30/20192,224539-711-553N/A
6/30/20192,027487-400-285N/A
3/31/20191,875452-279-184N/A
12/31/20181,700425-2062N/A
9/30/20181,633425-171-85N/A
6/30/20181,479418-123-31N/A
3/31/20181,325380-229-142N/A
12/31/20171,113314N/A-235N/A
9/30/2017915276N/A-268N/A
6/30/2017758193N/A-390N/A
3/31/2017668284N/AN/AN/A
12/31/2016582257N/A-287N/A
12/31/201546988N/A137N/A
12/31/201441650N/A179N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 603707 is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.9%).

Earnings vs Market: 603707 is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: 603707 is expected to become profitable in the next 3 years.

Revenue vs Market: 603707's revenue (23.9% per year) is forecast to grow faster than the CN market (14.6% per year).

High Growth Revenue: 603707's revenue (23.9% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: 603707's Return on Equity is forecast to be low in 3 years time (16.6%).

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Simply Wall St™
Simply Wall Street Pty Ltd
Level 7, 320 Pitt Street, Sydney
Download on the App StoreGet it on Google Play
Popular Markets
USAUUKINCAZA
About UsCareersPlansLogin
Help CenterLatest CoveragePodcastsAffiliate ProgramBusiness & Enterprise
Financial Services GuideTerms and ConditionsPrivacy PolicyLogos provided by Clearbit
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.